 |
|
|
| |
Phase 3 Study of Fostemsavir in Heavily Treatment-Experienced HIV-1-Infected Participants: BRIGHTE Week 24 Subgroup Analysis in Randomized Cohort Participants
|
| |
| |
Reported by Jules Levin
22nd International AIDS Conference; July 23-27, 2018; Amsterdam, the Netherlands
G. Latiff,1M. Kozal,2J. Aberg,3 G. Pialoux,4P. Cahn,5M. Thompson,6J.-M. Molina,7B. Grinsztejn,8R. Diaz,9A. Lazzarin,10M. Gummel,11A. Pierce,12P. Ackerman,13C. Llamoso,13M. Lataillade13
1Maxwell Centre, Durban, South Africa; 2Yale University School of Medicine, New Haven, United States; 3Mount Sinai Hospital, New York, United States; 4Hopital Tenon, Paris, France; 5Fundación Huesped, Buenos Aires, Argentina; 6AIDS Research Consortium of Atlanta, United States; 7Hôpital Saint Louis, Paris, France; 8Instituto de PesquisaClínicaEvandroChagas FIOCRUZ, Rio de Janeiro, Brazil; 9Federal University of São Paulo, Brazil; 10Ospedale San Raffaele, Milan, Italy; 11GlaxoSmithKline, Upper Providence, United States; 12ViiV Healthcare, Research Triangle Park, Durham, United States; 13ViiV Healthcare, Branford, United States.
|
| |
|
|
|
|
|
